Shameli K, Ahmad MB, Zargar M, Wan Yunus WMZ, Ibrahim NA, Shabanzadeh P, Ghaffari Moghaddam M: Synthesis and characterization of silver/montmorillonite/chitosan bionanocomposites by chemical reduction method and their antibacterial activity
Learn How GLPs and Peptides Can Help April 29th | 6:30 PM 8:00PM Location: Juventas Wellness: 835 E 18th Ave, Denver, CO 80218 Join us for Elevate Your Every Day , a thoughtfully curated wellness event designed to help you feel your bestinside and out
Its extended in vitro stability profile makes it suitable for receptor pharmacology research requiring sustained agonist activity across long incubation windows
Eli Lilly and Company Novo Nordisk #Pharma #GLP1 #Biologics #PharmaSupplyChain #DrugSafety Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Eli Lilly and Company #Retatrutide Phase 3 #Breakthrough: #Triple #Agonist (GLP-1/GIP/Glucagon) Driving Fat Burn, Appetite Control & Glucose Regulation Shows Up to 2.0% A1C Reduction + ~17% Weight Loss A major milestone in cardiometabolic innovation: Eli Lilly and Companys #retatrutide (GIP + GLP-1 + glucagon triple agonist) delivers best-in-class efficacy signals in Phase 3 (TRANSCEND-T2D-1) Key results (40 weeks) 1 Glycemic control A1C reduction: -1.7% to -2.0% vs placebo: -0.8% 2 Weight loss Up to -16.8% (~36.6 lbs) No plateau weight loss still ongoing 3 Cardiometabolic benefits Improvements in lipids, triglycerides, and blood pressure Key voice: Kenneth Custer Ph.D
